Results 231 to 240 of about 1,905,672 (358)

B4GALNT4‐Mediated Glycosylation of PDK1 Activates the PI3K‐AKT Signaling Pathway to Promote Prostate Cancer Progression

Advanced Science, EarlyView.
This study identifies B4GALNT4 as a key driver of prostate cancer (PCa). It shows that B4GALNT4 glycosylates PDK1 protein at the N531 site, which stabilizes the PDK1 and constitutively activates the PI3K‐AKT pathway. This mechanism promotes tumor cell proliferation, migration, and invasion. The findings establish the B4GALNT4‐PDK1 glycosylation axis as
Shaoqin Jiang, Mengqiang Li, Qingfu Su, Ruiling Dou, Shaoshan Lin, Jili Zhang, Xiaochen Sun, Haolan Yu, Wei Bao, Min Qu, Yan Wang, Chenghua Yang, Xu Gao   +12 more
wiley   +1 more source

Prognostic and immune microenvironment of a cancer-associated fibroblast-related genes signature for biochemical recurrence in prostate cancer. [PDF]

Medicine (Baltimore)
Zhang M, Min M, Zhang P, Li L, He W, Wang L.   +5 more
europepmc   +1 more source

The Positive Immunostaining of TMPRSS2-ERG is Not Associated With Unfavourable Outcomes and Biochemical Recurrence After Radical Prostatectomy in Turkish Patients

, 2018
Gülistan Gümrükçü, Burcu Onamay Celik, Selahattin Çalışkan, Selvinaz Ökzara, Orhan Koca, Çağatay Tosun, Ayşe Mine Önenerk, Fügen Aker   +7 more
openalex   +2 more sources

68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning

Journal of Nuclear Medicine, 2017
J. Calais, J. Czernin, M. Cao, A. Kishan, J. Hegde, N. Shaverdian, K. Sandler, F. Chu, C. King, M. Steinberg, I. Rauscher, N. Schmidt-Hegemann, T. Poeppel, P. Hetkamp, F. Ceci, K. Herrmann, W. Fendler, M. Eiber, N. Nickols   +18 more
semanticscholar   +1 more source

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

Advanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai   +6 more
wiley   +1 more source

PTEN and ERG Biomarkers as Predictors of Biochemical Recurrence Risk in Patients Undergoing Radical Prostatectomy. [PDF]

Diseases
Borz MB, Fetica B, Gliga MC, Sipos TC, Buhas BA, Schitcu VH.   +5 more
europepmc   +1 more source

Referee report. For: Diagnostic accuracy of 18F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of high-risk prostate cancer patients and patients with biochemical recurrence: protocol for an overview of reviews [version 1; peer review: 2 approved]

Laura Evangelista
openalex   +1 more source

Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review

Urologia internationalis, 2017
W. Artibani, A. Porcaro, V. De Marco, M. Cerruto, S. Siracusano   +4 more
semanticscholar   +1 more source

NIR‐Activatable Domino Cascade Catalysis Nanozyme Reactor for Multi‐Mechanism Synergistic Immunotherapy in Bladder Cancer

Advanced Science, EarlyView.
This study presents an intravesical delivery strategy of ferroptosis‐ and immunity‐inducing nanozyme‐loaded thermoresponsive hydrogels (FMCC@PNH) for enhanced bladder cancer therapy. Abstract Current intravesical therapies for bladder cancer after resection are limited by poor tissue penetration, off‐target effects, and insufficient efficacy.
Yongnan Jiang, Qingling Zhang, Yuhan Zhang, Xinlu Yu, Bo Jia, Yulong Dong, Yalong Wu, Kelong Fan, Xinquan Gu, Lei Ji, Wei Jiang, Bin Liu   +11 more
wiley   +1 more source

Preoperative predictors about lymph node metastasis and biochemical recurrence in high-risk prostate cancer patients: a clinic pathological retrospective study. [PDF]

BMC Urol
Wang C, Wang G, Xiao L, Du H, Xu Y, Li S, Yang X.   +6 more
europepmc   +1 more source